

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Ribo Life Science Co., Ltd.

蘇州瑞博生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL TRIAL OF RBD7022 INJECTION FOR THE TREATMENT OF HYPERLIPIDEMIA TO BE INITIATED IN CHINA

This announcement is made voluntarily by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide shareholders (the “**Shareholders**”) of the Company and potential investors with updates on the research and development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that RBD7022 Injection independently developed by the Group has completed the public registration for the Phase III clinical trial by the collaborator, Qilu Pharmaceutical Co., Ltd. (“**Qilu Pharmaceutical**”), and is about to initiate the Phase III clinical trial.

RBD7022 Injection is a siRNA drug targeting PCSK9. PCSK9 is an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as “LDL-C” or “bad cholesterol”. It can serve as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the Company granted Qilu Pharmaceutical the exclusive rights to develop, manufacture, and commercialize RBD7022 Injection in Chinese mainland, Hong Kong, and Macau.

RBD7022 Injection may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, March 2, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.